Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review

2019 ◽  
Vol 36 (2) ◽  
pp. 96-103 ◽  
Author(s):  
Camil Castelo-Branco ◽  
Iuliia Naumova
2020 ◽  
Author(s):  
Mina Amiri ◽  
Fatemeh Nahidi ◽  
Razieh Bidhendi-Yarandi ◽  
Davood Khalili ◽  
Maryam Tohidi ◽  
...  

Abstract Background and objective A limited number of studies have evaluated the effects of oral contraceptives (OCs) on the quality of life (QOL) of polycystic ovary syndrome (PCOS) patients. This study aimed to compare the effects of using OCs containing levonorgestrel (LNG) and those containing desogestrel (DSG), cyproterone acetate (CPA) or drospirenone (DRSP) for 6 months on the QOL with PCOS. Methods In this crossover randomized controlled 6-arm trial, 200 eligible patients with PCOS scheduled for OC therapy were randomly assigned to one of the 6 study arms. All 6 arms include two 6-month treatment periods, one period with OCs containing LNG, and the other with each of the 3 OCs containing DSG, CPA, or DRSP. Outcomes of interest were the total score of QOL and its domains, which were assessed using a specific and valid health‐related quality of life questionnaire for PCOS, which is consisted of six domains, including psychosocial–emotional, self-image, fertility, sexual function, hirsutism, and obesity– menstrual disorders.Results Finally, a total of 88 patients were analyzed for this study. The results showed that use of OCs containing DSG, CPA, and DRSP for 3 months was not associated with significant differences in the total scores of QOL compared to those OCs containing LNG, whereas, after 6 months of treatment, patients treated with OCs containing CPA had more improvements in their total scores of QOL, in comparison to OCs containing LNG (P < 0.042). We found no significant differences in QoL domains, including psychosocial–emotional, self-image, fertility, sexual function, hirsutism, and obesity-menstrual disorders after 3- 6 months of treatment with DSG, CPA, or DRSP, compared to LNG. The sequence and period effects were not significant in any of the analyses at 3 and 6 months of treatment. The carry-over effect was not significant for most outcomes assessed. Conclusions This crossover study demonstrated non-inferiority of OCs with newer generation progestins on different domains of QOL, in comparison with older compounds, although usage of products containing CPA was significantly associated with more improvement in total QOL of PCOS patients, compared to those containing LNG after 6-month of treatment. Clinical Trial Registration Number: IRCT201702071281N2.


2014 ◽  
Vol 291 (2) ◽  
pp. 451-455 ◽  
Author(s):  
Cristina Laguna Benetti-Pinto ◽  
Silvia Regina Ferreira ◽  
Armando Antunes ◽  
Daniela Angerame Yela

Author(s):  
Ewa Rzońca ◽  
Agnieszka Bień ◽  
Artur Wdowiak ◽  
Ryszard Szymański ◽  
Grażyna Iwanowicz-Palus

2010 ◽  
Vol 94 (5) ◽  
pp. 1812-1816 ◽  
Author(s):  
Rebecca L. Thomson ◽  
Jonathan D. Buckley ◽  
Siew S. Lim ◽  
Manny Noakes ◽  
Peter M. Clifton ◽  
...  

2018 ◽  
Vol 5 (2) ◽  
pp. 205510291878819 ◽  
Author(s):  
Sophie Williams ◽  
David Sheffield ◽  
Rebecca C Knibb

Polycystic ovary syndrome is an endocrine disorder amongst women, which can negatively impact quality of life. Research proposes that a more sensitive PCOS quality of life measure is needed. This study aims to develop and initially validate a quality of life scale for women with the condition in the United Kingdom. Women with PCOS (n = 714) took part in the development and initial validation of the 35-item polycystic ovary syndrome quality of life scale (PCOSQOL)(α = .95). Subscales include Impact of PCOS (α = .95), Infertility (α = .95), Hirsutism (α = .97) and Mood (α = .89). The PCOSQOL scale represents aspects of quality of life important to women with PCOS and may be more sensitive for use in the clinical and research settings.


Medicine ◽  
2019 ◽  
Vol 98 (50) ◽  
pp. e18323 ◽  
Author(s):  
Romilson de Lima Nunes ◽  
Isis Kelly dos Santos ◽  
Ricardo Ney Cobucci ◽  
Gabriel Soares Pichini ◽  
Gustavo Mafaldo Soares ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document